Oramed Pharmaceuticals Inc reports results for the quarter ended in February - Earnings Summary

Oramed Pharmaceuticals

14/07/2021 22:22

* Oramed Pharmaceuticals Inc  ORMP.OQ  reported a quarterly
adjusted loss of 17 cents​​ per share for the quarter ended in
February. The mean expectation of three analysts for the quarter
was for a loss of 17 cents per share.
* Revenue fell 1.3% to $665.00 thousand from a year ago; 
analysts expected $700.00 thousand. 
* Oramed Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 17 cents​.
* The mean earnings estimate of analysts had fallen by
about 21.2% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Oramed Pharmaceuticals Inc shares had risen by 1.6% this
quarter and gained 220.8% so far this year.
* The company reported a quarterly loss of $4.61 million.
* Wall Street's median 12-month price target for Oramed
Pharmaceuticals Inc is $23.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated July 14 at 09:22 p.m.. ​All
figures in July 14